Who are Iron Sucrose + Erythropoietin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ARM B: IV iron + epoietin zeta sequence, ARM A : IV iron + epoietin zeta, Oral Iron + Erythropoietin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iron-sucrose-erythropoietin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Iron Sucrose + Erythropoietin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iron Sucrose + Erythropoietin (Iron Sucrose + Erythropoietin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron supplement + Erythropoiesis-stimulating agent (ESA). Area: Hematology / Nephrology.

phase 3 Iron supplement + Erythropoiesis-stimulating agent (ESA) Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR) Hematology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Iron Sucrose + Erythropoietin (Iron Sucrose + Erythropoietin) — American Regent, Inc.. Iron sucrose replenishes iron stores while erythropoietin stimulates red blood cell production to treat anemia in patients with chronic kidney disease.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Iron Sucrose + Erythropoietin TARGET	Iron Sucrose + Erythropoietin	American Regent, Inc.	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR)
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Oral Iron + Erythropoietin	Oral Iron + Erythropoietin	American Regent, Inc.	phase 3	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Iron (Fe2+/Fe3+) and erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron supplement + Erythropoiesis-stimulating agent (ESA) class)

American Regent, Inc. · 2 drugs in this class
Centre Francois Baclesse · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iron Sucrose + Erythropoietin — Competitive Intelligence Brief. https://druglandscape.com/ci/iron-sucrose-erythropoietin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab